There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolyPid (PYPD) and Medtronic (MDT) with bullish sentiments.
PolyPid (PYPD)
In a report released today, Elliot Wilbur from Raymond James upgraded PolyPid to Buy, with a price target of $23.00. The company’s shares closed last Tuesday at $10.63.
According to TipRanks.com, Wilbur ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.6% and a 42.9% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Amneal Pharmaceuticals.
Currently, the analyst consensus on PolyPid is a Moderate Buy with an average price target of $23.00.
See today’s analyst top recommended stocks >>
Medtronic (MDT)
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Medtronic. The company’s shares closed last Tuesday at $114.06, close to its 52-week high of $122.15.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 15.3% and a 69.2% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Integra Lifesciences.
Medtronic has an analyst consensus of Strong Buy, with a price target consensus of $121.59, representing an 8.4% upside. In a report issued on November 18, Wells Fargo also maintained a Buy rating on the stock with a $127.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDT:
